Systemic Lupus Erythematosus (SLE)
B cells, a type of immune cell, are over-activated in SLE and produce antibodies that recognize healthy tissue (autoantibodies) which may be present years before a patient experiences symptoms. Blocking B cell activation may be the key to treating SLE. While Bruton’s tyrosine kinase (BTK) inhibitors have been shown to inhibit B cell activation in laboratory settings, none are currently available to treat SLE.
Blocking B cell activation may be the key to treating SLE.
In the last 60 years, only one new medicine, belimumab (Benlysta) has been approved to treat lupus. However, currently available treatments fail to provide a long-lasting benefit to many patients. Consequently, SLE remains a significant, medically underserved disease.
For more information, please visit:
For detailed information about completed and ongoing clinical studies for AC0058, ACEA’s BTK inhibitor, please visit www.clinicaltrials.gov.